Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

InVivo

- PMLiVE

Scientists uncover new drug target in fight against antimicrobial resistance

The discovery could lead to improved treatments for bacterial infections

- PMLiVE

MSD receives NICE recommendation for Keytruda in advanced endometrial cancer

More than 9,700 new cases of endometrial cancer are diagnosed every year in the UK

- PMLiVE

Merck unveils $3bn cost-cutting plan to support pipeline and new product launches

A new restructuring programme has been approved to support the initiative

- PMLiVE

MSD receives MHRA approval for adult-specific pneumococcal vaccine Capvaxive

Illnesses caused by Streptococcus pneumoniae are currently considered a major public health problem by WHO

- PMLiVE

GSK’s antibiotic Blujepa granted FDA approval to treat urinary tract infections

Blujepa is the first in a new class of oral antibiotics for uncomplicated UTIs in nearly 30 years

- PMLiVE

Merck gains rights to Hengrui’s heart disease candidate in deal worth almost $2bn

Cardiovascular diseases result in an estimated 17.9 million global deaths each year

- PMLiVE

MSD’s Welireg recommended by NICE to treat rare von Hippel-Lindau disease

Approximately one in every 70,000 people are affected by the tumour-causing genetic disease

- PMLiVE

Paratek announces positive late-stage results for Nuzyra in bacterial pneumonia

The condition, caused by various bacteria, affects more than 900,000 people in the US every year

- PMLiVE

WHO publishes latest report on development of antibacterial agents worldwide

AMR is designated as one of the top ten global public health threats facing humanity

- PMLiVE

MIT protein study could help accelerate development of new antibiotics

Histidine kinase is a crucial bacterial protein that regulates processes, including antibiotic resistance

- PMLiVE

WHO reveals ‘extensive’ worldwide overuse of antibiotics during COVID-19 pandemic

Findings from the report reveal factors that could have contributed to the spread of antimicrobial resistance

- PMLiVE

MSD and Astex announce expansion to oncology drug discovery collaboration

Astex will receive $35m upfront plus milestone payments totalling $500m per programme

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links